Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Oral ETX0282 in Healthy Subjects
NCT03491748Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- Mar 2018
- Primary completion
- Sep 2019
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ETX0282 in complicated urinary tract infection (cUTI) (12 arms), sponsored by Entasis Therapeutics. Primary endpoints: Number of participants with any non-serious adverse event, Number of participants with any serious adverse event and 11 more. Started Mar 2018; status: completed.
02
Drugs
ETX0282
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03491748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491748.